All In Biotech

Drug Trial Radar · NCT01222052

6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients

Randomized Multicenter Study Comparing 6xFEC With 3xFEC-3xDoc in High-risk Node-negative Patients With Operable Breast Cancer: Comparison of Efficacy and Evaluation of Clinico-pathological and Biochemical Markers as Risk Selection Criteria

Last checked: Nov 19, 2026Latest source record: Jun 26, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 4,150 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

4,150

Actual

Start

Jan 2002

Primary completion

Feb 2009

Study completion Feb 2019

Sponsor

Lead sponsor
Martin-Luther-Universität Halle-WittenbergAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GBG Forschungs GmbH
First posted
Oct 18, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In low-risk node-negative breast cancer patients adjuvant chemotherapy should be spared. The identification of this subgroup can be based either on clinical and pathological or on tumour-biological criteria. Due to their high prognostic impact, the tumour-biological invasion markers uPA/PAI-1 (urokinase-type plasminogen activator and its inhibitor PAI-1) are potential candidates to effectively assess the risk of relapse in node-negative breast cancer. This study is aimed to compare the risk assessment by the traditional clinico-pathological factors and by tumour-biological factors. The second study question refers to the comparison between an adjuvant combination treatment with FE100C\*6 and a sequential treatment with FE100C\*3 and Docetaxel\*3.

Conditions

  • Breast Cancer

Interventions

  • 5-Fluorouracil, Epirubicin, Cyclophosphamide, DocetaxelDrug

    Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-Free SurvivalTime frame: after 10 years follow up

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • GBG Forschungs GmbH

    Neu-Isenburg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.